Olympic Champion Rower James Cracknell Supports Award

CSJ Awards 2021

Double Olympic Champion Rower James Cracknell has presented a national charity award, which was sponsored by Morningside Pharmaceuticals.

The national Centre for Social Justice Awards’ Small Charity category winner was revealed virtually by James via a video recording to the Oasis Community Centre, in Worksop.

View the Video below to watch James present the award:

 

The CSJ Awards honour the best grassroots, poverty-fighting charities and social enterprises in Britain. All winners received a £10,000 prize, which will go towards providing their often life saving and life changing community work.

The CSJ chose Oasis Community Centre because the charity represents the very best of localism and the power of community spirit. They deal with some of the most complex issues in their area, identifying where need is most acute and being creative enough to come up with the solutions.

The Oasis Community Centre is a beautiful and vibrant 2-acre garden, hidden in the centre of the Kilton estate, Worksop. They operate as the heart of the community through running over 30 projects and activities for all ages, needs and interests. Through their therapeutic interventions, Oasis aim to reduce isolation, to improve health and wellbeing and increase the life opportunities and chances for all people in the area.

The CSJ chose Oasis as the Small Charity category winners because they have developed themselves intentionally to be responsive to the needs of local people and to fully support everyone who comes through their door, with no thresholds or cut-offs.

After winning their award Oasis said they would like to share their model with other community centres around the country, to demonstrate how a small charity with a big dream can make a difference to the world around them.

Congratulations to them from everyone at Morningside Pharmaceuticals.

LCCC Partnership Helps Sports Science Education

Leicestershire County Cricket Club's Morningside Medical Centre

Junior cricketers aged between 10 and 18 will be invited to the Morningside Medical Centre at Leicestershire County Cricket Club to learn about sports science and medicine following the naming rights renewal with Morningside Pharmaceuticals.

The medical centre, in LCCC’s Uptonsteel County Ground, Grace Road, was originally founded in 2016 and back then for the first time enabled players and visitors to be treated onsite for injuries or other medical requirements.

Since then the facility has become a critical treatment area for the players where specialist physio can be carried out, as well as urgent medical assistance provided in an emergency.

As the medical centre has become more established, it has developed into a hub for sports science and medicine, and the junior cricketers from LCCC’s Academy are now being invited to visit and learn more about these key study areas.

Dr Nik Kotecha OBE, Chairman of Morningside Pharmaceuticals, said: “At Morningside we’re immensely proud to continue our support of the Morningside Medical Centre, which is developing into a valuable sports and education hub.

“We’re passionate about promoting sports, healthy living and team work, as well as education, skills and helping young people into the world of work; which is why this initiative resonates so well with our company values.

“Developing sports science is an essential part of the club’s long term plans and in particular we are very supportive of their focus on how sports and physical activity promotes good health, mental health, wellbeing and team work.

“I hope the ongoing programme to invite the young cricketers into the medical centre to learn about sports science and medicine will inspire them to think about a career in these fascinating education disciplines.”

About 225 young cricketers will benefit from the progamme, which is being run through LCCC’s Academy of Cricket, by the Academy Strength and Conditioning Coach; Edd Riley-Gibson, and the Academy Physiotherapist; Ryan Smith.

Sean Jarvis, Chief Executive of LCCC, added: “I would like to thank Morningside Pharmaceuticals for their continued sponsorship of the Morningside Medical Centre, which is a huge part of our ambitions to involve the young people from our Academy in the education and community work taking place at the club.

“Working with the local community, particularly young people, is also very important to us, which is why introducing them to the medical centre’s work is a crucial part of our ambitions to raise awareness of sports science and other sports and medical focused careers.”

Care Packs Provided to Every Colleague

Care Pack for Mental Health Awareness Week

At Morningside Pharmaceuticals, the mental health and wellbeing of our employees is of paramount importance, which is why we were delighted to give a Care Pack to every colleague.

The packs were just a small way to say thank you to all of our hard working and dedicated people, for everything they have achieved throughout the Covid-19 pandemic.

Each pack contained a selection of treats designed to help people relax and unwind, as well as helpful support, advice and information about health and mental health.

The Care Packs were timed to coincide with Mental Health Awareness Week by the Mental Health Foundation, which this year is focussing on nature, and how it is central to our psychological and emotional health.

Morningside is a proud supporter of communities and in particular working with them to ensure everyone has affordable and accessible access to good health and mental health services and support.

Opinion: 5Cs Needed for UK-India Free Trade Agreement

Dr Nik Kotecha OBE

As the UK and India commit to working towards a future free trade agreement, Founder of Morningside Pharmaceuticals Ltd, Dr Nik Kotecha OBE, looks at the 5C’s which are essential to developing relations in the Post-Covid era.    

“Watching the hundreds of funeral pyres light up the night’s sky, as many regions of India struggle to bring the latest wave of Covid-19 under control, has touched the world.

This must have been first and foremost during Prime Minister Boris Johnson’s recent call with India’s PM, Narendra Modi, which also led to an extra £1billion in trade and investment being agreed between the two nations. India has passed 21.5 million cases, and the virus has affected not only the large cities but second cities and rural areas too.

Moving away from the difficulty of the here and now, the UK-India relationship has a bright future. Both Covid and Brexit underscore the importance of the UK’s future economic and trading relationships around the world. Aside from the obvious health effects, the Covid pandemic has depressed the UK economy, which is desperate for growth. Brexit has compounded the challenge as the UK needs to seek fresh relationships with important foreign markets such as India. It was notable that the recent integrated review by the government, which assesses the UK’s future foreign, defence and trading outlook, advocated a pivot to the “Indo Pacific.”

India is an important part of the UK’s post-Brexit future. The country is viewed romantically by many Brits who reference shared language, culture and history, but the current and future relationship can really flourish if we focus on certain areas. The UK-India relationship is meaningful to me for personal and business reasons. Whilst I have lived in the UK for almost 50 years, my family originates from India and I am proud of that. In 1991, I started a pharmaceuticals business called Morningside from a garage and three years later, we started doing business in India. Given my ties to the sub-continent, it was a real privilege when I took part in the business delegation when Prime Minister Theresa May visited India five years ago.

Going forward, the relationship between the UK and India should be characterised by the 5C’s. First, Covid, which both countries have and still suffer from. As we know, the second wave in India has been lethal and there are around 400,000 official cases per day, with the actual number likely to be much higher. The UK has been sending urgent medical supplies to India. It is heartening too that the UK and India have been working together on rolling out vaccines. Over a billion doses of the Oxford-AstraZeneca vaccine are being produced by the Serum Institute of India.

The second C is commerce, which was the focus of last week’s announcement which aims to double trade by 2030. UK-India trade is already worth £23 billion in 2019, and supports around half a million jobs in each other’s economies. Pharma is a particular sector of strength, with UK exports growing by 21.4% to £96.75m in 2019. I know from my visits that India is particularly keen on Britain’s burgeoning expertise in Life Sciences, MedTech and diagnostics.

A Confederation of Indian Industry survey in that same year highlighted the potential of Indian businesses in the UK, identifying 844 Indian companies operating in Britain, with combined revenues of over £48bn. UK political and business leaders appreciate that the Indian economy is expected to have one of the fastest growth rates in the G20 this year, and offers a market of 1.4 billion people. According to many estimates, India will be the third largest economy in the world by 2030. Given these encouraging statistics, therefore, it is no surprise that the UK views India as such an important economic and trade partner.

Third C for community refers to the British Indian community numbering some 1.5 million, which provides the rocket fuel in the relationship. They contribute hugely to the economic, cultural and social fabric of the UK. Whilst comprising just 4% of the UK population, they pay some 10% of taxes to the Treasury. The Anglo-Indian community is an entrepreneurial one. Research last year showed that Indian diaspora-owned companies have a combined revenue of over £35 billion and employ over 174,000 people. British Indians have reached the top of business, politics, the professions, science, the arts and other areas of public life. Indian culture has mainstream appeal whether it’s food and the ubiquitous curry house or film through Bollywood classics.

Fourth, the C of Commonwealth is an important glue in the relationship. India, of course, is the giant of the association. It joined in 1949 as a founding member when Nehru explained: “We join the Commonwealth because we think it is beneficial to us and to certain causes in the world that we wish to advance …….it is better to keep a co-operative association going which may do good in this world rather than break it.” Having hosted the last Commonwealth Summit, the UK is the Chair- in-Office and with India, they are two pivotal forces in working together to maximise its effectiveness.

The final C is climate change. Later on this year, in November the UK will host the global climate change talks, COP-26. India is a key country and is one of the countries which could be most affected by global warming. There is scope to collaborate on shared solutions, which is already happening on issues such as scaling up the electric mobility markets.

Whilst Boris Johnson’s recent planned visits to India have been cancelled twice, there is so much potential in the UK and India relationship. Together our two countries can work together on shared challenges and mutually beneficial trade. In cricket, India has just won an exciting Test Series at home, and (Covid-permitting) will hopefully play on English soil this summer. Whilst it’s winner-takes-all on the cricket field, we can plot a better future together by focusing on the 5 C’s, and enable the bilateral relationship to go from strength to strength.”

Export Deal Secured with India

10 Downing Street

Morningside Pharmaceuticals is delighted to be involved in one of 20 export deals signed, as part of the newly agreed Enhanced Trade Partnership between the UK and India.

The deal is connected to researching, developing and licencing new pharma products and is among an extra £1 billion of agreed additional UK-India trade and investment, which looks set to create 6,500 jobs.

In announcing the deal, The UK Prime Minister, Boris Johnson, said: “Like every aspect of the UK-India relationship, the economic links between our countries make our people stronger and safer. Each and every one of the more than 6,500 jobs we have announced today will help families and communities build back from coronavirus and boost the British and Indian economies.

“In the decade ahead, with the help of the new Partnership signed today and a comprehensive Free Trade Agreement, we will double the value of our trading partnership with India and take the relationship between our two countries to new highs.”

The package contains over £533m of new Indian investment into the UK, which is expected to create more than 6,000 jobs in vital and growing sectors such as health and technology, and £200m of these deals will support low carbon growth. The package includes a £240 million investment by the Serum Institute of India in the UK into their vaccine business and a new sales office which will create a large number of jobs.

The 20 British businesses alongside Morningside have secured new export deals with India worth more than £446 million, which will drive UK growth and create more than 400 British jobs.

Dr Nik Kotecha OBE, Chairman of Morningside Pharmaceuticals, said: “We are immensely proud to be included alongside other UK exporters in the new trading arrangements, which have been announced with India. This enhanced trading relationship is a great step forward towards a future free trade agreement, which would bring significant opportunities for exporters, as well as investment, into the UK and the Midlands.

“The Morningside companies have invested in India for many years, particularly in Research & Development and clinical trials, as well as through our manufacturing investments into developing new formulations of generic medicines for our UK and international markets.

“We are proud that much of the innovation takes place here in Leicestershire and is then ‘Technology Transferred’ to Indian partners to help bring new formulations of generic and branded medicines to the UK and global markets quicker.

“In this way, we are able to identify niche difficult to develop and manufacture molecules in a wide range of therapeutic areas. This makes our patients’ experience of taking their medicines easier, as well as delivering cost savings to the NHS and our International Aid partners.”

The announcement coincides with a plan from both sides to agree an Enhanced Trade Partnership, which it is hoped will unlock new opportunities for British businesses exporting to India and Indian businesses investing in the UK.

It is expected that the closer trading relationship will lead to the doubling of the value of UK-India trade by 2030, as well as signal of negotiations towards a comprehensive Free Trade Agreement.

Read more here on the UK Government’s .Gov website.

Our LOROS Rocket Takes Flight

LOROS Rocket Round Leicester

T-minus 3 months and counting until the LOROS Hospice Rocket Round Leicester giant rocket art trail lands on 19th July, before blasting off on Sunday, 26th September.

Everyone at Morningside Pharmaceuticals Ltd is incredibly excited about our sponsored rocket entitled ‘Hopes Dream and Wishes’ which will be among 40 giant ‘out of this world’ instillations scattered around Leicester city centre.

We can’t reveal the full design yet but here’s a sneak peak of the very talented Lynne Hollingsworth putting the finishing touches to it. As you can see we’re nearing Lift Off!

Visitors to the art trail will steer a voyage of discovery through the city’s streets and open spaces and help even life-long Leicester dwellers discover something new about where they live. Each Rocket will be designed by a professional artist and sponsored by local businesses. With a likely footfall of around 300,000 people, bringing in an expected £6 million to the local economy, Rocket Round Leicester will form a pivotal part of the city’s post-pandemic economic recovery, as well as a brilliant day out for everyone.

After the trail ends there will be the chance to say a final ‘goodbye’ at a Farewell Event, before each Rocket is auctioned to raise funds for LOROS Hospice to enable them to continue to care for over 2,500 terminally ill local people.

Dr Nik Makes the Power List 2021

Medicine Maker Power List 2021

We’re delighted to reveal that our Chairman, Dr Nik Kotecha OBE, has been named as one of 60 international leaders and innovators across the pharma industry to feature in the Power List 2021.

The list, compiled by The Medicine Maker magazine, celebrates the success stories of the best and brightest individuals in three distinct categories including Small Molecules, Biopharmaceuticals and Advanced Medicine. Dr Kotecha is honoured to be amongst the 20 leaders and innovators in the Small Molecules category.

To View the full Power List 2021 visit here.   

Readers of The Medicine Maker were invited to submit nominations for the Power List and the final list was compiled with the help of an anonymous judging panel.

Setting the scene for the 2021 Power List, the magazine said that the pharma industry has faced enormous challenges over the last 12 months as it strives to develop new vaccines and treatments to help the world find a way out of the pandemic.

Everyday life has changed drastically, but scientists and leaders in the pharma industry have demonstrated enormous dedication and resources to the fight – despite the uncertainty.

Now in 2021, the pandemic is not over – and won’t be for some time – but there are reasons to feel optimistic. Effective vaccines have been approved by many regulators for emergency use, existing drugs are being repurposed to help patients with severe COVID-19, and new drug development is vibrant. Small molecules, biopharmaceuticals, and even cell therapies are all being explored as potential medicines to combat COVID-19. The industry has genuinely outdone itself. And, alongside interventions against COVID-19, work continues tirelessly to address other crucial therapeutic areas.

Editor of The Medicine Maker, Stephanie Sutton, explains, “It has been remarkable to see the progress the pharma industry has made over the last 12 months. Companies have stepped up to the challenge and delivered; new vaccines typically take around a decade to reach the market, but COVID-19 vaccines have gone from discovery to real-world use in less than a year. Many individuals on our Power List have contributed to the fight against the pandemic, but everyone on the list – whether they are involved in COVID-19 vaccine and drug development or not – is playing a key role in moving us all towards a healthier world, from developing ground-breaking new treatments to devising new manufacturing strategies”.

Dr Kotecha added: “It’s a real honour to be included in the Power List 2021 , which has this year recognised 60 international leaders and innovators in the pharma industry.

“I’m truly humbled to feature alongside the best and brightest individuals working in Small Molecules, Biopharmaceuticals and Advanced Medicine.”

Apprenticeship Talk for Leicestershire Cares

Leicestershire Cares

Well done to two of our former apprentices who have taken part in a virtual careers advice session with students from Leicestershire’s secondary schools.

Executive Assistant Ria Wicks and HR Assistant Chloe Newton-Pell volunteered to share their journeys into the world of work at Morningside on the Leicestershire Cares webinar.

During the session both colleagues, who worked as well as gained a qualification from Loughborough College during their apprenticeships, spoke about their life experiences of building a career with Morningside.

They also talked about how their apprenticeships have helped them develop into their current roles, what they entail and their top tips for current school and college leavers who are thinking about their futures.

The live event, which was also filmed and will be shared with every secondary school in Leicestershire, was organised by Leicestershire Cares, which specialises in working with schools and young people to support employability.

To find out more about Leicestershire Cares visit here: https://www.leicestershirecares.co.uk/

Comic Relief 2021 at Morningside

Comic Relief at Morningside Pharmaceuticals

Comic Relief mania has once again descended on Morningside with colleagues wearing the usual wacky attire to raise money for charity.

There were – of course – red noses, lots of zany outfits and even flashing hats, which the Morningside team embraced as part of Comic Relief’s 2021 theme of needing the ‘power of funny, to turn laughs into lasting change’.

Due to social distancing restrictions colleagues were unable to get together for the usual festivities but a few did pose 2 meters apart for a mini photoshoot.

Despite the fun of the day, Comic Relief has a very real, serious side, which is making an enormous difference to the lives of people living in the UK and around the world.

To help the cause, every colleague who wished to take part donated to the charity, which provides safety to families who need support, tackles mental health stigma, takes action against domestic abuse and helps to give children a brighter future.

Opinion: Short/ Long Term Post Brexit Headaches?

Dr Nik Kotecha OBE

Pharma boss and Chairman of Morningside Pharmaceuticals, Dr Nik Kotecha OBE, examines whether the current challenges posed by the Post Brexit Trade Deal and the end of the Transition Period are temporary hiccups or a more permanent problem.

When the 11th hour Brexit Trade Deal arrived at the back end of 2020 most businesses hailed it as a breakthrough, largely because the prospect of no deal would have been so damaging to UK businesses.

On the one hand the deal has given most UK businesses certainty, which will enable companies to finally be able to make long term plans, as well as invest for the future.

I am a great admirer of how UK businesses are able to adapt and innovate, as their operating environments evolve, which will provide many opportunities to grow into new markets, as the UK continues to sign trade deals around the world.

However, on the other hand and despite business’ initial enthusiasm, the devil was always in the detail. Indeed, some sectors weren’t included in the deal, such as financial services.

It’s also clear that the new arrangements are not without their challenges. I talk to many business leaders and every company and sector is having to adapt and to adapt very quickly. My company, Morningside Pharmaceuticals, is no different, as we import and export our pharmaceutical products globally, as well as to the EU.

So the question to really ask is whether these are short term teething problems or a longer term fundamental challenge?

Pre-Brexit, we made extensive preparations for every eventuality, such as increasing buffer stocks and off-site warehousing; agreeing post-Brexit processes with freight forwarders; and ensuring EU supplier and customer readiness.

But inevitably there have been some issues since the new arrangements began, although it’s still too early to say whether these are all down to the new post-Brexit landscape, or are being amplified by the ongoing Covid-19 pandemic restrictions.

A few of the challenges we’ve faced so far include additional paper work, which has slowed turn-around time for shipping arrangements; extra shipping costs; customs brokers refusing work because of increased demand; and a shortage of haulage firms and drivers able, or willing, to take UK deliveries.

Some of the consequences of the Trade Deal have also affected our supply chain. One example is around specific Incoterms, which specify who is responsible for paying for and managing the shipment, insurance, documentation, customs clearance, and other logistical activities. This has led to a substantial amount of paperwork needing to be carried out by our EU suppliers, at a time when their resource time is inhibited by the pandemic.

To work through these issues we have taken a number of actions including; working closely with our EU partners and Freight Forwarding companies to refine shipping and customs processes and continuing our export strategy to focus on the rest of the world, as well as the EU.

We will also continue to work closely with the Department of Health & Social Care (DHSC), which is keen to support our sector where possible, as well as look to engage Government directly and through Trade Associations, like Chambers of Commerce, which I would encourage businesses to provide feedback to.

So to come back to the question, the majority of the current challenges we face should be short to medium term bumps in the road that get resolved in time as we learn to adapt. A longer term fundamental concern is the new trading arrangement with Northern Ireland and the issues around rules of origin, which must be resolved quickly.

As a business that has exported to more than 120 countries since our inception in the 1990s I have seen first-hand the opportunities which are out there, and the huge benefits on offer for UK Plc. It’s clear the new trade deals negotiated by the Department for International Trade (DIT) will offer UK businesses a real long-term advantage, including the potential for the UK to join trading blocks like the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP).

So, despite all of the headwinds we face, there are green shoots ahead and businesses must bear in mind that Brexit is a process, rather than a complete package from day one.

One very useful way to get a personalised list of actions for your business is through the Brexit Checker on www.Gov.uk website, which provides a quick ‘gap analysis’ of your business activities to help navigate through the new trading environment.

In time UK businesses will adapt to the new arrangements with the EU and begin to grow into exciting international markets, which offer huge growth potential for ‘Brand UK’.

It may just be a bit bumpy along the way.